Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

85 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-30

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present project aims to study the inflammatory and endothelial responses involved in the differences in clinical events related to both genotypes (ENG vs. ACVRL1) in HHT. Accordingly, a cross-sectional study is proposed to evaluate the differences in circulating inflammatory and endothelial biomarkers, including interleukines, adhesion molecules, chemokines and immune regulatory molecules between both HHT groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification and Characterization of Genetic Variants in Hereditary Angioedema

NCT05833620

Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

NOT_YET_RECRUITING

Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families

NCT00230620

Telangiectasia, Hereditary Hemorrhagic

RECRUITING

Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm

NCT02256163

Thoracic Aortic Aneurysm

COMPLETED

Biomarker for Hereditary AngioEdema Disease

NCT03029728

C1 Esterase Inhibitor Deficiency Angio Edema C4 Deficiency +5 more

COMPLETED

Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia

NCT00005313

Atherosclerosis Cardiovascular Diseases Heart Diseases +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background and rationale: Hereditary Hemorrhagic Telangiectasia (HHT) is a rare disease characterized by a multisystemic vascular dysplasia with autosomal dominant inheritance, mainly caused by mutations in ENG and ACVRL1 genes. Even though those mutations have been related to different clinical manifestations, the molecular mechanisms involved in each genetic variant have not been clarified. Methods: A cohort study will be carried out to compare the incidence of clinical events after a 12-months follow-up. The ability of these biomarkers to predict the clinical events will be assessed in a multivariate analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Hemorrhagic Telangiectasia HHT Rendu Osler Weber Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HHT1

Mutations in the ENG (endoglin) gene

Registry

Intervention Type OTHER

Non-interventional registry

HHT2

Mutations in the ALK-1 (activin receptor-like kinase) gene

Registry

Intervention Type OTHER

Non-interventional registry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Registry

Non-interventional registry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 75 years.
* Confirmed diagnosis of HHT, according to the Curaçao criteria or genetic diagnosis.
* Clinically stable condition at the time of inclusion, defined as score \< 7 points on the Epistaxis Severity Score (ESS).
* Having signed the informed consent, after having received all the information concerning the study.

Exclusion Criteria

* Major coronary or cerebrovascular event in the 3 months prior to inclusion.
* Serious intercurrent illnesses, such as acute infections, outbreaks of autoimmune or inflammatory pathology, active cancer, or other pathologies that, at the investigator's discretion, could interfere with the conduct of the study.
* Major surgery during the 2 months prior to inclusion.
* Pharmacological treatment maintained during the 3 months prior to inclusion with NSAIDs, corticosteroids or chemotherapy.
* Toxic habits, including severe smoking, alcohol or drug abuse, which in the opinion of the investigator could interfere with the conduct of the study.
* Pregnancy or puerperium.
* Any other condition that limits compliance with the visits or procedures established in the protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No